Recipharm and Sanofi have signed an agreement to transfer the Holmes Chapel site in the United Kingdom from Sanofi to CDMO Recipharm.
“Holmes Chapel brings Recipharm an ideal opportunity to accelerate its offering to customers with access to novel respiratory products,” said Thomas Eldered, CEO of Recipharm. “As an already successful CMO with several clients, we look forward to introducing new contracts to Holmes Chapel by utilizing our growing franchise in development services. Treatments for asthma and chronic obstructive pulmonary disease (COPD) are growing at a fast rate and we see many opportunities.”
The Holmes Chapel manufacturing facility includes more than 450 specialist employees, all of whom will transfer to Recipharm.
The transaction is expected to close in Q4 2018, after customary licenses and permissions have been obtained.
(Source: Recipharm AB)
